Abbott’s Lipidil NT 145mg listed with reimbursement

By Lee, Tak-Sun | translator Alice Kang

22.12.27 06:18:14

가나다라 0

Will be reimbursed from next month. at same price... fierce competition expected

On how GC Corp, which did not apply for reimbursement after being approved for its product that is being manufactured on consignment by Yuhan Corp, will move receives attention

The original developer of the hyperlipidemia treatment fenofibrate will be releasing a 145mg product that can be taken on an empty stomach. This is the second drug to be released, following Yuhan Corp.

As such, the two products are expected to compete fiercely in the market next year.

According to industry sources on the 26th, Abbott Korea’s Lipidil NT (fenofibrate 145mg) will be listed at a ceiling price of KRW 339 from the first of next month.

The price has been set the same as Yuhan Corp’s Fenowell Tab 145mg.

The Health Insurance Review and Assessment Service decided for Lipidil NT’s price to be set at the same level as Yuhan Corp.'s Fenowell Tab 145m

Lee, Tak-Sun(hooggasi2@dailypharm.com)

If you want to see the full article, please JOIN US (click)